11:40 AM EST - CohBar, Inc. : Has completed a study to evaluate the potential efficacy of its lead drug candidates, MOTS-c peptide analogs CB4209 and CB4211, in a well-established preclinical model of nonalcoholic steatohepatitis (NASH). With these positive study results, the Company continues to advance its lead drug candidates through IND enabling activities, with plans to initiate human clinical trials in early 2018. CohBar, Inc.
units V.COB.U are trading up $0.20 at $2.20.
